Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
choroidal neovascularization macular degeneration
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "choroidal neovascularization macular degeneration" in MCE Product Catalog:
1
Target:
Research Areas:
Acrizanib (LHA510) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
1
Target:
Research Areas:
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
Cat. No.: HY-153484A
CAS No.: 849758-52-7
Target:
Research Areas:
Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
Cat. No.: HY-P99830
CAS No.: 1227158-72-6
Synonyms: KH902
Target:
Research Areas:
Cat. No.: HY-W1048555A
Cat. No.: HY-153484
CAS No.: 959961-96-7
Target:
Research Areas:
Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
Cat. No.: HY-184141
CAS No.: 3037217-70-9
Target:
Research Areas:
EYE1090 is an orally active VEGFR2 inhibitor with an IC50 of 3 nM. EYE1090 inhibits angiogenesis, endothelial migration, VEGFR2-induced retinal leakage, and reduces choroidal neovascularization lesion size in mice. EYE1090 can be used for the research of age-related macular degeneration, diabetic retinopathy, choroidal neovascularization .
Cat. No.: HY-109020A
CAS No.: 1637434-72-0
Synonyms: LHA510 hydrochloride
Target:
Research Areas:
Acrizanib hydrochloride (LHA510 hydrochloride) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib hydrochloride inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib hydrochloride can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
Cat. No.: HY-109020R
CAS No.: 1229453-99-9
Synonyms: LHA510 (Standard)
Target:
Research Areas:
Acrizanib (Standard) (LHA510 (Standard)) is the analytical standard of Acrizanib (HY-109020). This product is intended for research and analytical applications. Acrizanib (LHA510) is a small-molecule vascular endothelial growth factor receptor 2 (VEGFR-2, KDR) inhibitor. Acrizanib inhibits the proliferation of BaF3-Tel-KDR cells dependent on VEGFR-2 activity, with an IC50 of 17.4 nM. Acrizanib can be used in research related to choroidal neovascularization and neovascular age-related macular degeneration .
Cat. No.: HY-P992151
Synonyms: LT1002
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Cat. No.: HY-183377
CAS No.: 1260071-76-8
Target:
EGFR Akt MMP HIF/HIF Prolyl-Hydroxylase mTOR VEGFR NF-κB Reactive Oxygen Species (ROS) Cadherin
Research Areas:
DMBT is an orally effective anti-tumor metastasis and anti-angiogenesis agent. DMBT downregulates key molecules such as EGFR/p-Akt/HIF-1α/VEGF/MMP-9, inhibits the HIF-1α/VE-cadherin (cadherin)/MMPs and Nrf2/HO-1 signaling pathways, and reduces hypoxia-induced ROS levels as well as the secretion and activity of MMP-9. DMBT inhibits hypoxia-induced vasculogenic mimicry, cancer cell migration, invasion and metastasis, and exhibits no obvious cytotoxicity to normal cells. DMBT reduces the area of laser-induced choroidal neovascularization lesions. DMBT can be used in studies related to breast cancer, melanoma and macular degeneration .
Cat. No.: HY-15492A
CAS No.: 319463-49-5
Synonyms: AG-013958 monohydrochloride
Target:
Research Areas:
AG-13958 monohydrochloride, a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .
Cat. No.: HY-184142
CAS No.: 3037217-73-2
Target:
Research Areas:
EYE1118 is an orally active, photoactivatable VEGFR2 inhibitor without acute hepatotoxicity. EYE1118 mediates light-enhanced inhibition via azide-functionalized receptor binding, and can utilize light-guided targeting to regulate its biodistribution in vivo. EYE1118 effectively inhibits angiogenesis, endothelial cell migration, VEGF-induced retinal leakage, and the size of choroidal neovascular lesions. EYE1118 has been applied in studies related to age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization .
Cat. No.: HY-113040B
Synonyms: (±)-17(S),18(R)-EETeTr
Target:
Research Areas:
(±)-(17S,18R)-Epoxyeicosatetraenoic acid ((±)-17 (S),18 (R)-EETeTr) is one of the constituent enantiomers of (±) 17 (18)-EpETE. (±) 17 (18)-EpETE is an active metabolite of the ω-3 fatty acid eicosapentaenoic acid, and also an agonist of sphingosine-1-phosphate receptor 1 (S1P1) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
